Showing 15 posts of 27 posts found.


Celltrion launches Humira biosimilar in US

July 7, 2023
Medical Communications Chronic Diseases, Humira, Yuflyma, arthritis, celltrion

South Korean biopharmaceutical company Celltrion has announced that its US branch – Celltrion USA – has launched a Humira (adalimumab) …

NICE recommends Janssen’s active psoriatic arthritis drug

May 28, 2021
Medical Communications Janssen, NICE, UK, arthritis

NICE have released a Final Appraisal Document (FAD) recommending Janssen’s tremfya (guselkumab) as a new option for treating active psoriatic …

NHS building

Abbvie psoriatic arthritis drug approved for use in Scotland

May 11, 2021
Manufacturing and Production AbbVie, NHS, arthritis, psoriatic arthritis

Abbvie’s RINVOQ (upadacitinib) drug, for the treatment of active psoriatic arthritis (PsA) in adults, has been approved for use in …

Janssen sign

Johnson & Johnson’s arthritis drug shows promising results in Phase III trial

March 16, 2021
Manufacturing and Production Janssen, Johnson & Johnson, PSA, Tremfya, arthritis

Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.

Eli Lilly front sign

University of Glasgow and Lilly sign £4.6m immunological disease partnership

February 15, 2021
Sales and Marketing Eli Lilly, University of Glasgow, arthritis, fibrosis, lilly, uofg

The University of Glasgow and Eli Lilly and Company have entered into a research collaboration, across four diseases, worth £4.6 …


Jyseleca secures European approval in rheumatoid arthritis

September 28, 2020
Research and Development, Sales and Marketing Europe, Jyseleca, arthritis, pharma

The European Commission has awarded approval to Gilead and Galpagos for their oral JAK inhibitor Jyseleca (filgotinib) as a treatment …


AbbVie granted EU marketing authorisation for new arthritis drug

December 19, 2019
Business Services AbbVie, EC, EU, arthritis, rheumatoid arthritis

AbbVie have announced that the European Commission (EC) have granted marketing authorisation for RINVOQ (upadacitnib). It’s a daily selective reversible …


Europe approves first subcutaneous version of biosimilar infliximab

November 26, 2019
Manufacturing and Production, Sales and Marketing arthritis, biosimilars, celltrion, infliximab, pharma

The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation …

Eli Lilly’s Taltz shows superiority over AbbVie’s Humira

December 18, 2018
Manufacturing and Production Eli Lilly, Humira, Taltz, arthritis, immune system

A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active …


Lilly dumps Hanmi’s rheumatoid arthritis med

February 20, 2018
Manufacturing and Production, Sales and Marketing Eli Lilly, arthritis, hanmi, pharma

Eli Lilly and Hanmi signed an exclusive licensing and collaboration agreement to develop the Bruton’s tyrosine kinase (BTK) inhibitor, HM71224, …


Lilly gets second shot at application for ‘blockbuster’ arthritis drug

August 31, 2017
Sales and Marketing Eli Lilly, arthritis, baricitinib, biotech, drugs, pharma, pharmaceutical

Earlier this year, Eli Lilly was on the receiving end of one of the most surprising setbacks in recent times …


Existing arthritis drug could save thousands in blood cancer treatment

August 3, 2017
Research and Development University of Sheffield, arthritis, biotech, blood cancer, drugs, life sciences, medicine, pharma, pharmaceutical

Findings by researchers at the University of Sheffield have indicated that thousands of pounds could be saved in blood cancer …

Sanofi and Regeneron score FDA approval for arthritis

May 23, 2017
Manufacturing and Production, Sales and Marketing FDA, Kevzara, arthritis, sarilumab

The FDA has awarded Sanofi and Regeneron’s Kevzara (sarilumab) approval for the treatment of moderate to severely active rheumatoid arthritis …

Roche says Phase III trials for giant cell arteritis drug met primary endpoint

June 6, 2016
Research and Development, Sales and Marketing Roche, arthritis, drug trial

Cancer drugmaker Roche (SIX: ROG) said late stage trials for its drug to treat giant cell arteritis (GCA) met its …

Latest content